novel
human
coronaviru
middl
east
respiratori
syndrom
coronaviru
merscov
caus
outbreak
sarslik
ill
middl
east
consid
threat
global
public
health
juli
world
health
organ
report
confirm
case
merscov
infect
includ
death
case
fatal
rate
studi
show
camel
like
primari
sourc
merscov
infect
human
rout
transmiss
camel
peopl
key
point
stop
transmiss
viru
far
clearli
understood
continu
threat
merscov
necessit
develop
effect
vaccin
studi
indic
recombin
receptorbind
domain
rrbd
protein
merscov
spike
good
candid
antigen
merscov
subunit
vaccin
howev
highli
purifi
protein
typic
inher
immunogen
usual
lack
mean
directli
stimul
innat
immun
system
besid
often
prone
degrad
henc
call
effici
deliveri
system
potent
immunostimul
jointli
denot
adjuv
evok
desir
antigenspecif
immun
respons
phenotyp
enabl
success
vaccin
aluminium
one
common
adjuv
nonliv
vaccin
record
success
use
human
vaccin
promot
antibodymedi
protect
immun
anoth
classic
adjuv
base
waterinoilemuls
formul
incomplet
freund
adjuv
ifa
recent
research
focus
adjuv
signal
pattern
recognit
receptor
prr
tolllik
receptor
tlr
cysteinephosphateguanin
cpg
oligodeoxynucleotid
odn
activ
b
cell
plasmacytoid
dendrit
cell
via
induc
innat
adapt
immun
current
develop
vaccin
adjuv
anoth
frequent
use
adjuv
polyriboinosin
acid
poli
c
synthet
dsrna
mimic
effect
natur
occur
dsrna
agonist
besid
enhanc
immun
respons
adjuv
tailormak
polar
immun
respons
exampl
ppolar
immun
achiev
addit
freund
adjuv
cpg
dna
antigen
hand
antibodi
respons
induc
alum
indic
increas
rel
howev
situat
respons
requir
protect
choic
one
regimen
anoth
might
counter
effect
led
addit
research
altern
adjuv
adjuv
combin
promot
balanc
mix
respons
recent
year
combin
antigen
one
adjuv
call
adjuv
system
approach
produc
vaccin
abil
gener
effect
immun
respons
adapt
pathogen
target
popul
use
multipl
adjuv
combin
antigen
present
cell
apc
activ
influenc
one
level
guid
subsequ
adapt
pathway
ultim
induc
robust
immun
respons
induct
robust
humor
includ
potent
neutral
antibodi
cellular
immun
respons
like
essenti
immedi
sustain
protect
immun
merscov
vaccin
design
studi
differ
adjuv
combin
regimen
includ
alum
ifa
cpg
poli
c
compar
effort
promot
balanc
immun
respons
bystand
rrbd
antigen
span
residu
merscov
murin
model
develop
effect
vaccin
merscov
infect
anim
studi
carri
strict
complianc
guid
care
use
laboratori
anim
peopl
republ
china
studi
protocol
approv
committe
ethic
anim
experi
chines
centr
diseas
control
prevent
procedur
perform
ethyleth
anesthesia
effort
made
minim
suffer
merscov
rrbd
protein
contain
fragment
span
residu
figur
genbank
number
prepar
use
bactobac
baculoviru
express
system
describ
detail
previous
requir
rrbd
measur
sdspage
figur
western
blot
figur
mice
polyclon
antibodi
spike
merscov
figur
vaccin
rrbd
protein
quantifi
bradford
method
rrbd
protein
combin
differ
adjuv
immedi
prior
immunis
aluminium
hydroxid
kindli
provid
north
china
pharmaceut
group
corpor
genetech
biotechnolog
develop
compani
odn
motif
contain
unmethyl
cpg
synthesis
takara
bio
inc
poli
c
ifa
purchas
sigma
st
loui
mo
singl
dose
rrbd
protein
combin
either
alum
alon
rbda
alum
plu
cpg
rbdac
alum
plu
poli
c
rbdap
cpg
ifa
rbdic
sixtoeightweekold
femal
balbc
mice
anim
care
centr
chines
academi
medic
scienc
beij
china
randomli
distribut
eight
group
eight
mice
group
vaccin
three
time
rrbd
protein
interv
either
intramuscular
im
subcutan
sc
rout
tabl
sera
collect
week
vaccin
heatinactiv
min
detect
rbdspecif
neutral
antibodi
mice
scarifi
week
last
immunis
lung
spleen
harvest
detect
schemat
vaccin
analysi
timelin
shown
figur
elisa
use
detect
merscov
rbdspecif
antibodi
respons
immunis
mice
briefli
elisa
plate
precoat
rrbd
protein
ngwell
overnight
block
nonfat
milk
h
serial
dilut
sera
eight
mice
group
ad
plate
incub
h
follow
four
wash
phosphatebuff
salin
pb
contain
tween
pbst
bound
antibodi
incub
hrpconjug
antimous
igg
sigma
h
reaction
visualis
use
tmb
peroxidas
substrat
solut
invitrogen
stop
addit
absorb
nm
measur
use
elisa
plate
reader
wellscan
mk
cutoff
valu
set
neg
control
antibodi
avid
determin
use
elisa
method
describ
vermont
et
al
briefli
sera
dilut
titr
ascend
concentr
chaotrop
agent
nascn
ad
plate
plate
incub
min
room
temperatur
rt
wash
develop
determin
total
igg
control
antibodi
specif
elisa
use
measur
total
antimerscov
igg
titr
pre
postvaccin
sera
sampl
convent
neutral
assay
use
live
merscov
cumbersom
perform
biosafeti
facil
therefor
adapt
merscov
pseudoviru
system
sensit
quantit
conduct
biosafeti
facil
report
zhao
et
al
brief
cell
cotransfect
plasmid
encod
codonoptim
merscov
protein
plasmid
encod
envdefect
luciferaseexpress
genom
use
fugen
hd
reagent
roch
basel
switzerland
supernat
contain
merscov
pseudoviru
harvest
h
posttransfect
use
singlecycl
infect
cell
plate
cellswel
tissuecultur
plate
grown
overnight
supernat
contain
pseudoviru
preincub
serial
dilut
mous
sera
h
addit
cell
cultur
refe
fresh
medium
h
later
incub
addit
h
cell
wash
pb
lyse
use
lysi
reagent
includ
luciferas
kit
promega
aliquot
cell
lysat
transfer
costar
flatbottom
luminomet
plate
corn
costar
follow
addit
luciferas
substrat
promega
rel
light
unit
determin
immedi
gaomax
luminomet
promega
experi
carri
triplic
pseudoviru
inhibit
pi
rate
calcul
rel
luciferas
unit
mock
sera
rel
luciferas
unit
immun
serum
given
dilut
rel
luciferas
unit
mock
sera
evalu
antigenspecif
tcell
respons
induc
vaccin
regim
elispot
assay
perform
describ
previous
briefli
plate
coat
per
well
mgml
antimous
antibodi
bd
pharmingen
overnight
block
h
rt
freshli
harvest
splenocyt
per
well
lung
lymphocyt
eight
mice
group
isol
describ
previous
mgml
synthesis
peptid
librari
overlap
merscov
rbd
amino
acid
ad
well
triplic
next
biotinyl
detect
antibodi
bd
pharmingen
streptavidinhorseradish
peroxidas
ad
blot
develop
addit
aec
substrat
solut
produc
colour
spot
rt
incub
dark
final
spotform
cell
sfc
count
phorbol
pma
ionomycin
ad
positivecontrol
group
wherea
negativecontrol
group
receiv
stimuli
number
peptidespecif
secret
cell
calcul
subtract
negativecontrol
valu
sfc
count
cba
analysi
conduct
investig
level
cytokin
secret
mice
three
time
immun
brief
splenocyt
per
well
eight
mice
group
distribut
plate
stimul
pool
rbd
peptid
plate
incub
supernat
harvest
concentr
cytokin
includ
measur
use
mous
cytokin
kit
bd
bioscienc
fac
calibur
flow
cytomet
becton
dickinson
data
analys
use
fcap
array
softwar
becton
dickinson
statist
analyse
conduct
use
oneway
anova
function
spss
softwar
packag
pvalu
less
consid
indic
statist
signific
assess
humor
immun
respons
differ
immunis
regimen
mice
immunis
rrbd
protein
combin
differ
adjuv
three
time
interv
serum
sampl
collect
week
vaccin
total
antimerscov
rbd
igg
antibodi
titr
determin
elisa
result
indic
rrbd
protein
combin
adjuv
includ
alum
ifa
cpg
poli
c
could
induc
rbdspecif
igg
antibodi
respons
major
mice
second
immunis
vaccin
mice
rbdspecif
igg
antibodi
could
detect
even
first
immunis
seroconvers
rate
differ
group
follow
first
second
immunis
shown
tabl
shown
figur
discern
increas
igg
titr
third
immunis
compar
second
immunis
among
vaccin
regim
rbdac
rbdic
elicit
highest
total
igg
titr
p
figur
besid
differ
igg
titer
two
group
signific
figur
similarli
shown
figur
differ
igg
titer
rbda
rbdap
group
signific
rbdspecif
antibodi
lower
adjuv
control
group
three
vaccin
respons
variou
vaccin
regim
investig
use
nascn
antibodydisplac
elisa
measur
antibodi
avid
figur
mice
receiv
rbdac
rbdic
regim
higher
antibodi
avid
week
final
vaccin
receiv
rbda
rbdap
regim
also
noteworthi
high
antibodi
avid
correl
high
igg
titr
mice
characteris
immun
respons
differ
vaccin
regim
igg
isotyp
analys
perform
week
final
vaccin
use
secondari
antibodi
shown
figur
e
f
mice
immunis
rbdac
rbdic
produc
higher
titr
mice
immunis
rbda
rbdap
also
ratio
reveal
skew
respons
mice
receiv
rbdac
rbdic
regim
contrast
rbda
rbdap
regim
produc
higher
ratio
indic
respons
titr
rbdspecif
antibodi
howev
significantli
differ
among
vaccin
group
nneutral
antibodi
sera
mice
immunis
differ
vaccin
regim
evalu
pseudovirusbas
neutral
assay
low
level
neutral
antibodi
detect
week
first
second
vaccin
aall
sera
test
although
total
igg
antibodi
level
almost
peak
second
vaccin
highest
level
neutral
antibodi
induc
last
vaccin
figur
pseudoviru
inhibit
pi
rate
shown
figur
shown
rbdac
regim
highest
neutral
antibodi
activ
p
surprisingli
low
level
detect
neutral
antibodi
sera
mice
immunis
sc
rbdic
regim
although
sera
group
igg
titr
high
rbdac
group
third
immunis
expect
neutral
antibodi
detect
sera
mice
immunis
individu
adjuv
without
rrbd
antigen
result
suggest
merscov
rrbd
protein
induc
potent
antimerscov
neutral
antibodi
respons
combin
certain
adjuv
alum
cpg
combin
maximis
neutral
antibodi
respons
rrbd
antigen
characteris
cellular
immun
respons
elicit
vaccin
regim
singl
cell
quantifi
elispot
system
local
cellular
immun
respons
assess
use
lymphocyt
spleen
lung
immunis
mice
peptid
librari
use
stimul
lymphocyt
describ
materi
method
section
result
express
number
sfc
per
input
cell
adjuv
without
rrbd
elicit
clear
cellular
respons
spleen
week
third
immunis
figur
neither
rbda
rbdap
induc
signific
cellular
immun
respons
contrast
rbdac
rbdic
regimen
enhanc
detect
system
cellular
immun
respons
furthermor
rbdic
regimen
induc
greatest
cellular
immun
respons
greatest
number
cell
spleen
p
signific
cellular
immun
respons
lung
induc
rbdic
regim
although
produc
cell
detect
immunis
mice
figur
therefor
conclud
rbdac
rbdic
regim
could
induc
systemat
cellular
immun
respons
mice
rbdic
regim
could
elicit
signific
local
cellular
immun
respons
lung
cytokin
profil
spleen
cell
immunis
mice
analys
stimul
rbdspecif
peptid
cba
splenocyt
mice
immunis
rbdac
rbdic
produc
figur
contrast
produc
splenocyt
follow
immunis
rrbd
combin
adjuv
figur
differ
product
among
group
signific
compar
group
splenocyt
mice
immunis
rbdac
induc
significantli
higher
level
figur
figur
p
indic
adjuv
alum
cpg
combin
could
induc
mix
immun
respons
rrbd
antigen
model
merscov
though
respons
reveal
polar
isotyp
elisa
elispot
detect
similarli
high
level
also
indic
mix
immun
respons
could
induc
rbdic
regim
figur
differ
shown
figur
rbdap
regim
induc
highest
level
p
indic
respons
inclin
consist
result
igg
isotyp
howev
detect
vaccin
group
data
shown
coronavirus
adapt
rapidli
new
host
adapt
merscov
allow
viru
effici
replic
human
would
major
public
health
concern
sinc
adapt
could
trigger
pandem
develop
effect
vaccin
critic
prevent
potenti
merscov
pandem
previou
studi
shown
vaccin
sarscov
rbd
induc
highli
potent
neutral
antibodi
significantli
inhibit
sarscov
infect
therefor
propos
vaccin
rbd
merscov
belong
betacoronaviru
genu
sarscov
might
also
inhibit
merscov
infect
induc
neutral
antibodi
respons
merscov
du
et
al
identifi
recombin
protein
contain
acid
fragment
residu
truncat
rbd
merscov
spike
protein
fuse
human
igg
fc
fragment
abl
induc
vaccin
mice
strong
merscov
sspecif
antibodi
block
bind
rbd
dipeptidyl
peptidas
human
merscov
receptor
effect
neutral
merscov
infect
besid
show
residu
protein
merscov
induc
signific
neutral
antibodi
respons
suggest
region
potenti
develop
merscov
vaccin
mou
et
al
show
polyclon
antibodi
rabbit
rbd
protein
fragment
residu
effici
neutral
viru
infect
howev
none
studi
evalu
immunogen
rrbd
protein
systemat
anim
model
recent
et
al
ssuggest
possibl
develop
recombin
rbd
protein
contain
residu
effect
safe
mucos
mer
vaccin
intranas
rout
presenc
poli
c
adjuv
mous
model
need
vaccin
abil
gener
effect
immun
respons
led
combin
antigen
one
adjuv
adjuv
system
approach
adjuv
system
approach
aid
develop
vaccin
gener
effect
immun
respons
studi
role
three
ifa
cpg
poli
c
rrbd
subunit
vaccin
investig
aim
induc
effect
immun
respons
use
tailor
adjuv
combin
deliveri
rout
consist
studi
vaccin
regim
contain
rrbd
induc
rbdspecif
cellular
humor
immun
respons
howev
robust
immun
respons
elicit
mice
immunis
rbdac
rbdic
regim
unexpect
result
absenc
neutral
antibodi
sera
rbdic
immunis
mice
despit
antirbd
specif
igg
titr
similar
rbdic
rbdac
regim
understand
riddl
detect
aantibodi
avid
differ
vaccin
regim
aavid
elisa
howev
result
show
high
antibodi
avid
correl
high
igg
titr
mice
rbdic
rbdac
group
specul
mayb
adjuv
destroy
conform
rrbd
cover
antigen
bind
site
anoth
probabl
caus
low
titer
neutral
antibodi
sera
rbdic
immunis
mice
deliveri
rout
subcutan
known
subcutan
may
associ
degrad
inject
site
lead
decreas
bioavail
whatev
studi
process
compar
studi
regim
studi
induc
lower
titr
neutral
antibodi
exampl
alum
plu
cpg
group
show
highest
titer
neutral
antibodi
immun
group
rrbd
protein
studi
acquir
mice
neutral
antibodi
titr
differ
may
caus
detect
method
neutral
antibodi
show
materi
method
part
neutral
antibodi
studi
detect
pseudoviru
system
conduct
biosafeti
facil
differ
induc
neutral
antibodi
among
differ
group
shown
clearli
subclass
immunoglobulin
induc
immun
indirect
measur
rel
contribut
cytokin
vs
cytokin
characteris
immun
respons
differ
vaccin
regim
igg
isotyp
includ
analys
perform
expect
rbda
regim
produc
respons
high
ratio
contrast
mice
receiv
rbdac
rbdic
regim
reveal
skew
respons
consist
rbdac
rbdic
regim
induc
systemat
cellular
immun
respons
mice
elispot
analysi
high
level
cba
also
proof
cellular
immun
respons
mice
besid
mice
rbdac
group
high
level
index
skew
respons
taken
togeth
rbdac
induc
mix
immun
respons
though
respons
inclin
origin
intent
mix
respons
better
protect
similarli
rbdic
regim
induc
mix
respons
howev
piti
rbdic
regim
could
induc
effect
neutral
antibodi
import
factor
prophylact
vaccin
studi
merscov
rrbd
combin
adjuv
alum
cpg
produc
robust
immun
respons
indic
combin
alum
cpg
optim
strategi
im
rrbd
antigen
deliveri
murin
model
result
facilit
futur
merscov
vaccin
design
result
present
studi
also
support
import
adjuv
system
approach
although
adjuv
combin
alway
produc
desir
respons
seen
rbdic
consist
result
present
studi
cpg
plu
alum
found
induc
protect
humor
well
cellular
immun
mice
immunis
recombin
haemagglutinin
vaccin
protect
influenza
viru
challeng
ideal
immun
cpg
alum
combin
may
result
mutual
complement
two
adjuv
well
known
alum
promot
antibodymedi
protect
immun
howev
alum
poor
induc
cellular
immun
respons
recent
adjuv
includ
oilinwat
emuls
shown
improv
efficaci
avian
influenza
protect
suggest
even
diseas
humor
immun
confer
protect
cellular
immun
respons
may
necessari
vaccin
design
key
featur
cpgodn
use
vaccin
adjuv
includ
abil
elicit
cell
certain
condit
cytotox
cell
respons
addit
abil
divert
preexist
respons
neonat
elderli
mice
toward
phenotyp
thu
expect
combin
alum
cpg
prove
applic
rang
infecti
diseas
defeat
current
immunis
strategi
except
choic
adjuv
combin
optim
protect
antigen
practic
item
antigen
adjuv
ratio
dose
vaccin
regimen
often
rout
administr
strongli
impact
effect
safeti
vaccin
formul
case
experiment
vaccin
initi
test
anim
model
evalu
immunogen
rrbd
protein
thoroughli
necessari
test
protect
effect
rrbd
subunit
immunis
anim
model
merscov
infect
date
rhesu
macaqu
report
gener
pneumonialik
symptom
within
h
merscov
infect
test
effect
rrbd
immunis
rhesu
macaqu
consider
effort
made
establish
small
anim
model
merscov
infect
though
lung
cell
syrian
hamster
express
receptor
merscov
suscept
merscov
infect
recent
mous
model
merscov
infect
reportedli
gener
transduct
mice
adenovir
vector
express
futur
expect
protect
effect
rbdac
vaccin
investig
murin
model
merscov
infect
